#GLP-1 class
Coverage of the GLP-1 receptor agonist family and its successors.
How semaglutide produces weight loss
Semaglutide works mainly in the brain, suppressing appetite via GLP-1 signalling. Here is what the STEP trials found and what stops when the drug stops.
Tirzepatide in youth: first real-world data
A study of 74 youth prescribed tirzepatide at three clinics found lower blood sugar and BMI. What can the first real-world numbers actually show?
Do other diabetes drugs stop on a GLP-1?
In 3,660 adults starting a GLP-1 or tirzepatide, the count of other glucose-lowering drugs fell for 17.2% of patients and rose for 44.0%.
GLP-1 drugs: how background therapy shifts
A 3,660-patient Polish study found 44% of patients on new incretin-class drugs had more background agents added, 39% saw no change, and 17% had agents removed.
Semaglutide and MASH: what ESSENCE found
Semaglutide has a licensed indication for MASH, the inflamed form of fatty liver disease. Here is what the ESSENCE trial showed, and what it has not.
Tirzepatide vs carpal tunnel: a 2026 study
A 2026 cohort study found tirzepatide users had lower rates of carpal tunnel syndrome than users of other GLP-1 or anti-obesity drugs.
GLP-1 therapy and IBS: TriNetX findings
In 6,665 matched IBS patients, GLP-1 receptor agonist use was tied to lower coded rates of abdominal pain, bloating, and chronic diarrhoea.
SELECT trial: semaglutide and dementia risk
A SELECT sub-analysis found semaglutide 2.4 mg slowed a blood-based dementia risk score in 2,970 adults over 65. What the finding shows, and what it does not.
Semaglutide nanoparticles: 2026 HIP study
A 2026 study loaded semaglutide into microfluidic lipid nanoparticles and found a 6-fold permeability gain in intestinal cell models.
Tirzepatide: 10-year CVD risk in SURMOUNT-1
Post-hoc SURMOUNT-1 analysis: tirzepatide 15 mg cut predicted 10-year CVD risk by 1.92 pp at 72 weeks, widening to a 5.15 pp gap over placebo at three years.
Peru obesity drugs: budget impact explained
A 2026 analysis of 76,819 Peruvians found that full obesity drug coverage could cost up to S/143 billion per year. Here is what the numbers mean.
Oral GLP-1 drugs for obesity, no diabetes
A 2026 network meta-analysis of nine trials ranks oral semaglutide and orforglipron as top performers for weight loss in adults with obesity without diabetes.